Justin Hasenkamp
Overview
Explore the profile of Justin Hasenkamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shumilov E, Levien L, Mazzeo P, Jung W, Leha A, Koch R, et al.
Leuk Lymphoma
. 2024 Dec;
:1-12.
PMID: 39660415
Allogeneic stem cell transplantation (alloSCT) represents a curative option for patients with relapsed/refractory (r/r) aggressive lymphomas. We compared outcomes of alloSCT in r/r PTCL and r/r DLBCL pts ( = ...
2.
Sockel K, Neu A, Goeckenjan M, Ditschkowski M, Hilgendorf I, Kroger N, et al.
Blood
. 2024 Jul;
144(14):1532-1542.
PMID: 39007722
Improved long-term survival rates after allogeneic hematopoietic cell transplantation (alloHCT) make family planning for young adult cancer survivors an important topic. However, treatment-related infertility risk poses challenges. To assess pregnancy...
3.
Finke J, Schmoor C, Ayuk F, Hasenkamp J, Verbeek M, Wagner E, et al.
Bone Marrow Transplant
. 2024 Apr;
59(8):1204.
PMID: 38654115
No abstract available.
4.
Finke J, Schmoor C, Ayuk F, Hasenkamp J, Verbeek M, Wagner E, et al.
Bone Marrow Transplant
. 2024 Mar;
59(7):936-941.
PMID: 38493275
ATOS is a prospective observational study evaluating the outcome of patients receiving anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation. Primary endpoint was severe GvHD and relapse-free survival (SGRFS). GvHD...
5.
Panagiota V, Kerschbaum J, Penack O, Stein C, Arends C, Koenecke C, et al.
Hemasphere
. 2023 Oct;
7(10):e957.
PMID: 37799345
Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric...
6.
Martinovic D, Hasenkamp J, Jung W, Tucholski F, Maas J, Wulf G
EJHaem
. 2023 May;
4(2):563-565.
PMID: 37206281
No abstract available.
7.
Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft H, et al.
J Clin Invest
. 2023 May;
133(12).
PMID: 37159273
BACKGROUNDAdoptive transfer of EBV-specific T cells can restore specific immunity in immunocompromised patients with EBV-associated complications.METHODSWe provide results of a personalized T cell manufacturing program evaluating donor, patient, T cell...
8.
Eder L, Martinovic D, Mazzeo P, Ganster C, Hasenkamp J, Thomson J, et al.
Curr Oncol
. 2023 Jan;
30(1):1146-1150.
PMID: 36661736
We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing...
9.
Shumilov E, Aperdannier L, Schmidt N, Szuszies C, Neesse A, Hoffknecht P, et al.
Cancers (Basel)
. 2022 Aug;
14(15).
PMID: 35954410
COVID-19 vaccines have become an integral element in the protection of cancer patients against SARS-CoV-2. To date, there are no direct comparisons of the course of COVID-19 infection in cancer...
10.
Dopfer-Jablonka A, Steffens S, Muller F, Mikuteit M, Niewolik J, Cossmann A, et al.
BMC Infect Dis
. 2022 Apr;
22(1):403.
PMID: 35468758
Background: Immunocompromised people (ICP) and elderly individuals (older than 80 years) are at increased risk for severe coronavirus infections. To protect against serious infection with SARS-CoV-2, ICP are taking precautions...